Browse our anti-RPS6KA3 (RPS6KA3) Antibodies

Full name:
anti-Ribosomal Protein S6 Kinase, 90kDa, Polypeptide 3 Antibodies (RPS6KA3)
On are 148 Ribosomal Protein S6 Kinase, 90kDa, Polypeptide 3 (RPS6KA3) Antibodies from 19 different suppliers available. Additionally we are shipping RPS6KA3 Proteins (13) and RPS6KA3 Kits (1) and many more products for this protein. A total of 173 RPS6KA3 products are currently listed.
CLS, HU-3, ISPK-1, MAPKAPK1B, MPK-9, MRX19, p90-RSK2, pp90RSK2, RSK, RSK2, S6K-alpha3
list all antibodies Gene Name GeneID UniProt
RPS6KA3 110651 P18654
RPS6KA3 6197 P51812

Show all species

Show all synonyms

Most Popular Reactivities for anti-RPS6KA3 (RPS6KA3) Antibodies

Select your species and application

anti-Mouse (Murine) RPS6KA3 Antibodies:

anti-Human RPS6KA3 Antibodies:

anti-Rat (Rattus) RPS6KA3 Antibodies:

All available anti-RPS6KA3 Antibodies

Go to our pre-filtered search.

Top referenced anti-RPS6KA3 Antibodies

  1. Human Polyclonal RPS6KA3 Primary Antibody for EIA - ABIN358394 : Yang, Matsuda, Bialek, Jacquot, Masuoka, Schinke, Li, Brancorsini, Sassone-Corsi, Townes, Hanauer, Karsenty: ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. in Cell 2004 (PubMed)
    Show all 5 references for 358394

  2. Human Monoclonal RPS6KA3 Primary Antibody for ICC, FACS - ABIN969386 : Dehan, Bassermann, Guardavaccaro, Vasiliver-Shamis, Cohen, Lowes, Dustin, Huang, Taunton, Pagano: betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. in Molecular cell 2009 (PubMed)
    Show all 2 references for 969386

  3. Human Monoclonal RPS6KA3 Primary Antibody for EIA, IF - ABIN1108903 : Koutsilieris, Mitsiades, Bogdanos, Dimopoulos, Karamanolakis, Milathianakis, Tsintavis: Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. in Clinical cancer research : an official journal of the American Association for Cancer Research 2004 (PubMed)

More Antibodies against RPS6KA3 Interaction Partners

Mouse (Murine) Ribosomal Protein S6 Kinase, 90kDa, Polypeptide 3 (RPS6KA3) interaction partners

  1. The purified protein can be fully activated in vitro by phosphorylation with protein kinases ERK2 (show MAPK1 Antibodies) and PDK1 (show PDPK1 Antibodies).

  2. Downregulation of Rps6ka3 is a promising strategy for the treatment of multiple sclerosis.

  3. Data show that the phosphoinositide-dependent kinase 1 (PDK1 (show PDPK1 Antibodies))-p90 (show GPAM Antibodies) kDa ribosomal S6 kinases (Rsks) Rsk1 (show RPS6KA1 Antibodies)/2 pathway is critical for establishment and maintenance of a normal Langerhans cells (LC) network.

  4. RSK2 regulates craniofacial development including tooth development and patterning via novel transcriptional targets

  5. The results of this study show that RSK2 loss-of-function is associated in the dentate gyrus with multi-level alterations that encompass modifications of glutamate (show GRIN1 Antibodies) receptor channel properties, synaptic transmission.

  6. We propose that loss of function mutations in RSK2 that lead to Coffin-Lowry syndrome are related to defects in neuronal growth due to impaired RSK2-dependent PLD1 activity resulting in a reduced vesicle fusion rate and membrane supply.

  7. RSK2 interacted and phosphorylated GSK-3beta (show GSK3b Antibodies) at Ser9. Notably, GSK-3beta (show GSK3b Antibodies) phosphorylation at Ser9 was suppressed in RSK2(-/-) mouse embryonic fibroblasts.

  8. Pin1 (show PIN1 Antibodies) plays a critical role in tumorigenesis plausibly via physical interaction with RSK2 and reciprocal phosphorylation

  9. This study showed that RSK2 signaling contributes to morphine analgesia in the tail withdrawal response.

  10. Results show increased protein levels of Rsk1 (show RPS6KA1 Antibodies) and Rsk2 in the striatum of Huntington disease (show HTT Antibodies) mice and and striatal cells transfected with full-length mutant Huntingtin (show HTT Antibodies).

Human Ribosomal Protein S6 Kinase, 90kDa, Polypeptide 3 (RPS6KA3) interaction partners

  1. we discuss the function of the RSK2 signaling axis by interactions with binding partners in cancer development--{REVIEW}

  2. Results showed that RSK2 gene was overexpressed in osteosarcoma patients cells and its knockdown increased cell apoptosis, enhanced cell chemosensitivity, inhibits proliferation and migration, and weakened tumor formation.

  3. Upregulated expression of RSK2 is associated with breast cancer.

  4. Data show that the 90 kDa ribosomal protein S6 (show RPS6 Antibodies) kinases RSK1 (show RPS6KA1 Antibodies) and RSK2 play a key role in the homing of ovarian cancer cells in metastatic sites by regulating cell adhesion and invasion.

  5. RSK1 (show RPS6KA1 Antibodies) and 3 but not RSK2 are down-regulated in breast tumour and are associated with disease progression. RSK (show RPS6KA1 Antibodies) may be a key component in the progression and metastasis of breast cancer.

  6. This case is one of the few examples where RPS6KA3 mutations are associated with a non-specific X-linked mental retardation.

  7. Results indicate that the phosphorylation of EphA2 (show EPHA2 Antibodies) at Ser (show SIGLEC1 Antibodies)-897 is controlled by RSK (show RPS6KA1 Antibodies) and the RSK (show RPS6KA1 Antibodies)-EphA2 (show EPHA2 Antibodies) axis might contribute to cell motility and promote tumour malignant progression.

  8. miR (show MLXIP Antibodies)-191 represses proliferation in primary human fibroblasts via targeting multiple proto-oncogenes, including CDK9 (show CDK9 Antibodies), NOTCH2 (show NOTCH2 Antibodies), and RPS6KA3.

  9. This is the first report of exon skipping from an exonic mutation of RPS6KA3, demonstrating that a missense mutation and concomitant disruption of normal splicing contribute to the manifestation of CLS (show CLS Antibodies)

  10. SL0101 and BI-D1870 induce distinct off-target effects in mTORC1-p70S6K (show RPS6KB1 Antibodies) signaling, and thus, the functions previously ascribed to RSK1 (show RPS6KA1 Antibodies)/2 based on these inhibitors should be reassessed.

RPS6KA3 Antigen Profile

Antigen Summary

This gene encodes a member of the RSK (ribosomal S6 kinase) family of serine/threonine kinases. This kinase contains 2 non-identical kinase catalytic domains and phosphorylates various substrates, including members of the mitogen-activated kinase (MAPK) signalling pathway. The activity of this protein has been implicated in controlling cell growth and differentiation. Mutations in this gene have been associated with Coffin-Lowry syndrome (CLS).

Alternative names and synonyms associated with RPS6KA3

  • ribosomal protein S6 kinase polypeptide 3 (Rps6ka3) antibody
  • ribosomal protein S6 kinase, 90kDa, polypeptide 3 (RPS6KA3) antibody
  • CLS antibody
  • HU-3 antibody
  • ISPK-1 antibody
  • MAPKAPK1B antibody
  • MPK-9 antibody
  • MRX19 antibody
  • p90-RSK2 antibody
  • pp90RSK2 antibody
  • RSK antibody
  • RSK2 antibody
  • S6K-alpha3 antibody

Protein level used designations for RPS6KA3

90 kDa ribosomal protein S6 kinase 3 , MAP kinase-activated protein kinase 1b , MAPK-activated protein kinase 1b , MAPKAP kinase 1b , MAPKAPK-1b , RSK-2 , S6K-alpha-3 , p90-RSK 3 , p90RSK3 , ribosomal S6 kinase 2 , ribosomal protein S6 kinase 2 , ribosomal protein S6 kinase alpha-3 , insulin-stimulated protein kinase 1

110651 Mus musculus
6197 Homo sapiens
Selected quality suppliers for anti-RPS6KA3 (RPS6KA3) Antibodies
Did you look for something else?